---
title: "Gujarat Kidney & Super Speciality Ltd (GKSL) — Share Price, Financials & Analysis"
symbol: "GKSL"
company: "Gujarat Kidney & Super Speciality Ltd"
canonical: "https://tapetide.com/stocks/GKSL"
isin: "INE0V0W01025"
nse_symbol: "GKSL"
bse_code: "544666"
sector: "Healthcare Services"
industry: "Hospitals"
market_cap_cr: 1366.67
generated_at: "2026-09-13T19:37:24.057Z"
---

# Gujarat Kidney & Super Speciality Ltd (GKSL)

Canonical page: https://tapetide.com/stocks/GKSL

## Company

- **NSE Symbol:** GKSL
- **BSE Code:** 544666
- **ISIN:** INE0V0W01025
- **Sector:** Healthcare Services
- **Industry:** Hospitals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2025-12-30
- **CEO:** Mr. Pragnesh Yashwantsinh Bharpoda
- **Employees:** 338
- **Face Value:** ₹2
- **F&O Eligible:** No
- **Website:** gujaratsuperspecialityhospital.com

## About

Incorporated in 2019, Gujarat Kidney and Super Speciality Limited specializes in providing multispeciality healthcare services.[1]

## Latest Price

- **Price:** ₹171.09
- **Change:** -2.13 (-1.23%)
- **Open:** ₹174.35
- **Day High:** ₹176.45
- **Day Low:** ₹170
- **Previous Close:** ₹173.22
- **Volume:** 120195
- **As Of:** 2026-09-11T09:59:32+00:00

## Key Fundamentals

Observed at 2026-09-11T04:37:06.825743Z.

- **Market Cap:** ₹1366.67 Cr
- **Classification:** Microcap
- **P/E (reported):** 81.8
- **P/E (TTM):** 79.95
- **EPS (TTM):** ₹2.14
- **Book Value:** ₹32.03
- **Price to Book:** 5.41
- **Dividend Yield:** 0%
- **ROE:** 35.02%
- **ROCE:** 39.85%
- **Debt to Equity:** 0.11
- **Revenue (yearly):** ₹82.01 Cr
- **Net Income:** ₹16.04 Cr
- **EBITDA:** ₹26.94 Cr
- **52-Week High:** ₹180.9
- **52-Week Low:** ₹98.36
- **RSI (14):** 75.68

## Key Insights

### Strengths

- Company is expected to give good quarter

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 172 days.
- Working capital days have increased from 55.7 days to 91.1 days

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | — | 13.61% | 572.57% |
| ebitda margin growth | 30% | -21.38% | -32.93% | -64.06% |
| net income growth | 10.42% | 68.84% | — | — |
| revenue growth | 11.82% | 103% | 146.13% | 152.44% |
| roce | 38.29% | 177.89% | — | 22.21% |
| roe | 10.14% | 120.81% | 16.4% | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 9.41 | 11.79 | 9.78 | 15.26 | 12.93 | 23.25 | 30.58 | 34.29 |
| Expenses | 4.55 | 7.19 | 7.17 | 6.64 | 7.81 | 16.35 | 24.28 | 25.92 |
| Operating Profit | 4.86 | 4.6 | 2.61 | 8.62 | 5.12 | 6.9 | 6.3 | 8.37 |
| OPM % | 51.65 | 39.02 | 26.69 | 56.49 | 39.6 | 29.68 | 20.6 | 24.41 |
| Other Income | 0.04 | 0.05 | 0.05 | 0.01 | 0.09 | 0.06 | 0.71 | 0.69 |
| Interest | 0.16 | 0.17 | 0.16 | 0.18 | 0.28 | 0.6 | 0.82 | 0.66 |
| Depreciation | 0.74 | 0.88 | 0.9 | 0.96 | 0.9 | 1.33 | 1.51 | 1.44 |
| Profit before tax | 4 | 3.6 | 1.6 | 7.49 | 4.03 | 5.03 | 4.68 | 6.96 |
| Tax % | 26.25 | 29.72 | 16.88 | 27.77 | 28.54 | 26.44 | -2.99 | 23.56 |
| Net Profit | 2.96 | 2.53 | 1.34 | 5.4 | 2.88 | 3.7 | 4.82 | 5.32 |
| EPS in Rs | 18.39 | 15.53 | 0.23 | 0.85 | 0.47 | 0.37 | 0.64 | 0.66 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- |
| Sales | 0 | 5 | 40 | 82 | 101 |
| Expenses | 0 | 3 | 24 | 55 | 74 |
| Operating Profit | 0 | 2 | 17 | 27 | 27 |
| OPM % | — | 41 | 41 | 33 | 26 |
| Other Income | 0 | 1 | 0 | 1 | 2 |
| Interest | 0 | 0 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 3 | 5 | 5 |
| Profit before tax | 0 | 2 | 13 | 21 | 21 |
| Tax % | 0 | 25 | 26 | 21 | — |
| Net Profit | 0 | 2 | 10 | 17 | 17 |
| EPS in Rs | -0.5 | 85.5 | 1.66 | 1.97 | 2.14 |
| Dividend Payout % | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Equity Capital | 0.2 | 0.2 | 11 | 16 |
| Reserves | 0 | 11 | 15 | 237 |
| Borrowings | 0 | 6 | 8 | 29 |
| Other Liabilities | 4 | 4 | 21 | 16 |
| Total Liabilities | 4 | 21 | 55 | 298 |
| Fixed Assets | 0 | 14 | 31 | 129 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets | 4 | 7 | 24 | 169 |
| Total Assets | 4 | 21 | 55 | 298 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Cash from Operating Activity | 0 | 1 | 14 | -4 |
| Cash from Investing Activity | 0 | 0 | -18 | -214 |
| Cash from Financing Activity | 0 | 0 | 6 | 228 |
| Net Cash Flow | 0 | 1 | 2 | 11 |
| Free Cash Flow | 0 | 2 | -5 | -15 |
| CFO/OP | 0 | 70 | 99 | -14 |

### Ratios

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- |
| Debtor Days | — | 321 | 138 | 172 |
| Inventory Days | — | — | — | 82 |
| Days Payable | — | — | — | 339 |
| Cash Conversion Cycle | — | 321 | 138 | -84 |
| Working Capital Days | — | 100 | -24 | 91 |
| ROCE % | — | 19 | 52 | 14 |

## Shareholding Pattern

### Quarterly

| Category | Mar 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- |
| Promoters | 99.1% | 71.45% | 71.45% | 71.45% |
| FIIs | 0% | 10.47% | 4.88% | 4.88% |
| DIIs | 0% | 1.67% | 0.56% | 0.56% |
| Government | 0% | 0% | 0% | 0% |
| Public | 0% | 11.57% | 10.64% | 10.64% |
| Others | 0.9% | 4.84% | 12.46% | 12.46% |
| No. of Shareholders | 7 | 7 | 18301 | 18301 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 12 / 6 / 1

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 170.51 | Buy |
| EMA (10) | 169.61 | Buy |
| SMA (20) | 162.44 | Buy |
| EMA (20) | 162.3 | Buy |
| SMA (50) | 143.27 | Buy |
| EMA (50) | 148.93 | Buy |
| SMA (100) | 136.99 | Buy |
| EMA (100) | 137.39 | Buy |
| SMA (200) | — | Neutral |
| EMA (200) | — | Neutral |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 70.87 | Sell |
| MACD (12,26,9) | 9.46 | Buy |
| Stochastic (14,3,3) | 75.74 | Neutral |
| ADX (14) | 67.07 | Buy |
| Williams %R (14) | -31.91 | Neutral |
| ATR (14) | 6.5 | High Volatility |
| ROC (12) | 12.31 | Buy |
| Stoch RSI (14) | 0 | Buy |
| UO (7,14,28) | 39.3 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-04 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=87256146-94a8-41cf-bf21-8fc3a382fb31.pdf) |
| 2026-09-03 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d9e6199f-8953-4fc0-b59c-ec51491c7a2f.pdf) |
| 2026-09-03 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fa0bb468-e84d-4558-abb4-c6a7e97d8eda.pdf) |
| 2026-09-03 | [AGM To Be Held On 28-09-2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=25d44983-b3e1-4775-982e-dc35059edb4b.pdf) |
| 2026-09-01 | [Intimation Of Pre-Advertisement-Notice Of Annual General Meeting Of The Company](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d9d7940c-139c-41bd-bd9a-46e471cf000a.pdf) |
| 2026-08-24 | [Shareholder Meeting / Postal Ballot-Scrutinizer"s Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8b453736-2fc4-4fc4-b78b-361d44e50fcf.pdf) |
| 2026-08-24 | [Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d331ecbe-b385-4ec6-9ebe-b6b516a44296.pdf) |
| 2026-08-24 | [Board Meeting Outcome for Outcome Of Board Meeting Held On 24-08-2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4bd5d008-aa05-4517-9e31-c39c7a5ad150.pdf) |
| 2026-08-24 | [Announcement under Regulation 30 (LODR)-Change in Management](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7226c9a3-232d-450e-8ce0-c904cf19903f.pdf) |
| 2026-08-24 | [Outcome Of Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c0ca2f06-50dd-43fe-8cef-9c06c833b34c.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-27 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7a2d927f-a874-490d-99e4-a2fa831b2463.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-14 | [Financial Results For Quarter Ended June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=201404bc-6aa0-4a2e-8fae-3a75eda0ba64.pdf) |
| 2026-05-28 | [Financial Results As On 31.03.2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9808ca9d-2527-4db7-abc2-df48d21b54d8.pdf) |
| 2026-03-13 | [Results-Delay in Financial Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=33d645a2-613d-40a7-8ca8-ea0d29a3a7c9.pdf) |
| 2026-02-14 | [Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine Months Ended December 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1a115186-ab67-4e5e-8391-f36107b06fdc.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 8h - BSE and NSE each levied Rs. 10,000 fine for delayed Board meeting intimation; company paid on 16 Apr 2026. | [Intimation About Payment Of Fine Levied Under Regulation 29 Of SEBI (LODR) Regulations 2015 8h - BSE and NSE each levied Rs. 10,000 fine for delayed Board meeting intimation; company paid on 16 Apr 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/0f48efbf-4a68-4e6b-997c-c108bee82ee3.pdf) |
| 7h - Postal ballot passed three resolutions, including healthcare expansion fund use and financial statement revision. | [Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 7h - Postal ballot passed three resolutions, including healthcare expansion fund use and financial statement revision.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/cb71830d-e020-45e4-8adb-1d492ae9e32f.pdf) |
| 7h - Postal ballot on 25 Apr 2026 passed three resolutions, including fund utilisation, financial statement revision, and secretarial auditor appointment. | [Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 7h - Postal ballot on 25 Apr 2026 passed three resolutions, including fund utilisation, financial statement revision, and secretarial auditor appointment.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/d02d498c-21cf-459b-87dd-8a3bbb594fe8.pdf) |
| 7h - Board appointed secretarial auditor Dharmendra Bhaliya and internal auditor Siddharth Shah for FY2025-26; resubmitted Feb14 results corrected. | [Board Meeting Outcome for Outcome For Board Meeting Outcome For Board Meeting Hold On 19Th March 2026. 7h - Board appointed secretarial auditor Dharmendra Bhaliya and internal auditor Siddharth Shah for FY2025-26; resubmitted Feb14 results corrected.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/0898feb5-8666-4eb1-84d7-073d8fce0470.pdf) |
| 7 Apr - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026; all shares remain in demat form. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 7 Apr - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026; all shares remain in demat form.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6c16ec64-8c07-4c7f-b403-f4c578585583.pdf) |
| 6h - Board approved new Company Secretary, 100% WOS incorporation, and noted shareholder approvals on April 27, 2026. | [Appointment of Company Secretary and Compliance Officer 6h - Board approved new Company Secretary, 100% WOS incorporation, and noted shareholder approvals on April 27, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/f902665c-b72b-4774-88aa-fb472383047e.pdf) |
| 6h - Board appointed secretarial/internal auditors; resubmitted Feb 14 financial results for Q2/H1 ended 30 Sep 2025. | [Announcement under Regulation 30 (LODR)-Change in Management 6h - Board appointed secretarial/internal auditors; resubmitted Feb 14 financial results for Q2/H1 ended 30 Sep 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/086cd00a-1a9d-4fb4-ada5-8c113d725b4d.pdf) |
| 6h - Appointed secretarial auditor Dharmendra Bhaliya and internal auditor Siddharth Shah for FY2025-26; refiled corrected Feb 14, 2026 minutes. | [Announcement under Regulation 30 (LODR)-Change in Management 6h - Appointed secretarial auditor Dharmendra Bhaliya and internal auditor Siddharth Shah for FY2025-26; refiled corrected Feb 14, 2026 minutes.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/f5dcf82f-52d4-44d2-80b3-cf507b736ce5.pdf) |
| 5h - Board approved new Company Secretary and WOS incorporation for healthcare expansion in Bharuch, effective 27 April 2026. | [Announcement under Regulation 30 (LODR)-Acquisition 5h - Board approved new Company Secretary and WOS incorporation for healthcare expansion in Bharuch, effective 27 April 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/fe172d72-3af1-4a55-860d-bf985622c6bd.pdf) |
| 30 Apr - Company filed initial large corporate disclosure; outstanding borrowing was Rs 1.23 crore and not a large corporate. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 30 Apr - Company filed initial large corporate disclosure; outstanding borrowing was Rs 1.23 crore and not a large corporate.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5532ad5c-c509-4183-99bf-a238feb2fe46.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:37:24.057Z.